The selection of commercially viable drug candidates and advancing their development
toward worldwide markets is a complex and challenging task that requires people with a broad
range of different qualifications and drug development know-how.

Bryant E. Fong

Board member

Back to team

Bryant is Founding General Partner and Managing Director of BioMark Capital, a life sciences private equity fund formed in 2013. Prior to BioMark Capital, Bryant was Managing Director and Co-Head of Venture Capital at Burrill & Company, where he spent almost 16 years investing and managing investments in private and public biotechnology companies. His recent successful investments included Pharmasset (acquired by Gilead Sciences), Ferrokin Biosciences (acquired by Shire plc), Ceptaris Therapeutics (acquired by Actelion SA), Novadaq (NVDQ), WaveTec Vision (acquired by Alcon SA), ADMA Biologics (ADMA), NEOS Therapeutics (NEOS), and JHL Biotech (TT:6540). Prior to joining Burrill & Company, Byrant was a biochemist and molecular biologist with two early stage biotechnology companies located in the San Francisco Bay Area. His research experiences include recombinant protein expression in yeast, development of linear artificial chromosomes for pathway engineering/heterologous gene transfer in yeast and catalytic RNA technology. Bryant currently serves on the Boards of Directors of a number of private life science companies. He earned bachelor’s degree with honors in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley.